Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27470616 | 1.00 | IDO1 (0.42) | IDO1PDPK1CYP11B2SIGMAR1ACP3 | |
| SCHEMBL13926003 | 1.00 | IDO1 (0.42) | IDO1PDPK1CYP11B2SIGMAR1ACP3 | |
| SCHEMBL13974427 | 0.89 | IDO1 (0.45) | IDO1 | |
| SCHEMBL14855827 | 0.89 | IDO1 (0.45) | IDO1 | |
| SCHEMBL14644896 | 0.89 | IDO1 (0.45) | IDO1 | |
| SCHEMBL29325108 | 0.88 | IDO1 (0.40) | IDO1PDPK1SIGMAR1ACP3 | |
| SCHEMBL19435767 | 0.88 | IDO1 (0.40) | IDO1PDPK1SIGMAR1ACP3 | |
| SCHEMBL16284910 | 0.79 | IDO1 (0.40) | IDO1PDPK1CYP11B2ACP3SRD5A1 | |
| SCHEMBL2322453 | 0.78 | IDO1 (0.48) | IDO1PDPK1CYP11B2SIGMAR1SRD5A1 | |
| SCHEMBL29980773 | 0.78 | IDO1 (0.48) | IDO1PDPK1CYP11B2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-10-12 | — | — | US | disclosed |
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-10-12 | — | — | US | disclosed |
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-10-12 | — | — | US | disclosed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | IDO1 2370/4885PDPK1 2836/4885CYP11B2 326/4885 |
| US-20170291885-A1 | METHOD FOR PREPARING ENAMIDE COMPOUND AND RUTHENIUM COMPLEX CATALYST USED THEREIN | ENY2, ENO1, IDH1 | IDO1 358/4885PDPK1 4443/4885CYP11B2 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.